CN103007081B - 一种治疗非酒精性脂肪肝的中药组合物 - Google Patents
一种治疗非酒精性脂肪肝的中药组合物 Download PDFInfo
- Publication number
- CN103007081B CN103007081B CN2012105263748A CN201210526374A CN103007081B CN 103007081 B CN103007081 B CN 103007081B CN 2012105263748 A CN2012105263748 A CN 2012105263748A CN 201210526374 A CN201210526374 A CN 201210526374A CN 103007081 B CN103007081 B CN 103007081B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- chinese medicine
- medicine composition
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 235000005881 Calendula officinalis Nutrition 0.000 claims abstract description 12
- 241000218176 Corydalis Species 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- 241000594394 Hedyotis Species 0.000 claims abstract description 10
- 240000000785 Tagetes erecta Species 0.000 claims abstract 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- 241000482268 Zea mays subsp. mays Species 0.000 claims description 11
- 239000009526 Fructus Akebiae Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 4
- 241000722953 Akebia Species 0.000 claims description 2
- 241000772044 Boenninghausenia Species 0.000 claims description 2
- 240000007160 Hedyotis costata Species 0.000 claims description 2
- 235000014435 Mentha Nutrition 0.000 claims description 2
- 241001072983 Mentha Species 0.000 claims description 2
- 241000219295 Portulaca Species 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000245214 Mentha canadensis Species 0.000 abstract 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000009973 maize Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 11
- 241000736851 Tagetes Species 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- -1 Herba Menthae Substances 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗非酒精性脂肪肝的中药组合物，该中药组合物是由茯苓，玉米花，薄荷，八月札，万寿菊花，石椒草，黑节草，徐长卿，元胡，桑椹子，甘草，马齿苋制成。
Description
技术领域
本发明属于中药技术领域，尤其是涉及一种治疗非酒精性脂肪肝的中药组合物。
背景技术
非酒精性脂肪肝是一种无过量饮酒史，以肝实质细胞脂肪变性和脂肪贮积为特征的临床病理综合症。最常见的症状表现为乏力，部分病人自觉有右上腹轻度不适、隐痛或上腹胀痛等非特异症状，严重者可出现皮肤瘙痒、食欲减退、恶心、呕吐等症状。目前尚无治疗非酒精性脂肪肝的特效手段，一些化学药物的治疗效果及安全性问题尚需进一步检验。本发明制备得到的中药组合物治疗非酒精性脂肪肝，取得了良好的效果。
发明内容
本发明的目的在于提供一种治疗效果好、有效率高、对人体无毒副作用的治疗非酒精性脂肪肝的中药组合物。
本发明的目的是这样实现的，根据中医药理论，利用中药独特的药性，采用茯苓，玉米花，薄荷，八月札，万寿菊花，石椒草，黑节草，徐长卿，元胡，桑椹子，甘草，马齿苋制成，按照一定的配伍要求，经过加工制成。
制备本发明中药组合物由下述原料药制成：茯苓20-35份，玉米花20-35份，薄荷20-30份，八月札20-30份，万寿菊花15-25份，石椒草15-25份，黑节草15-25份，徐长卿10-18份，元胡10-18份，桑椹子8-15份，甘草8-15份，马齿苋8-15份。
本发明中药组合物原料药的最佳重量份为：茯苓30份，玉米花30份，薄荷25份，八月札25份，万寿菊花20份，石椒草20份，黑节草20份，徐长卿15份，元胡15份，桑椹子12份，甘草12份，马齿苋12份。
本发明中药的药理作用如下：
茯苓：甘、淡、平。归心、脾、肺、肾经。渗湿利水，健脾和胃，宁心安神。用于小便不利，水肿胀满，痰饮咳逆，呕吐，脾虚食少，泄泻，心悸不安，失眠健忘，遗精白浊等。
玉米花：甘、凉。疏肝利胆。用于肝炎、胆囊炎。
薄荷：辛、凉，归心、肺、肝经。疏散风热，清利头目，利咽，透疹，疏肝解郁。用于风热感冒，温病初起，麻疹不透，风疹瘙痒，肝郁气滞，胸闷胁痛等。
八月札：微苦、性平。归肝、胃、膀胱经。疏肝和胃，活血止痛，软坚散结，利小便。用于肝胃气滞，脘腹、胁助胀痛，饮食不消，下痢便泄，疝气疼痛，腰痛，经闭痛经，瘿瘤瘰疬，恶性肿瘤等。
万寿菊花：苦、凉。清热解毒，止咳。用于风热感冒，咳嗽，痢疾，腮腺炎，乳痈，牙痛，口腔炎症，目赤肿痛。
石椒草：辛；苦；性凉。肺；胃经。疏风解表，清热解毒，行气活血。用于感冒，扁桃体炎，支气管炎，肺炎，肾盂肾炎，胃痛腹胀，血栓闭塞性脉管炎，腰痛，跌打损伤等。
黑节草：辛、微苦、温。归肝、肾经。清热除湿，活血消肿。疟疾，肝炎，眼结膜炎，内湿骨痛，骨折肿痛，外伤出血。
徐长卿：辛、热，归脾、胃、肾经。温中止痛，杀虫止痒，活血解毒，消肿用于胃病，牙痛，风湿痹痛，腰痛，脘腹疼痛，胆囊炎，小便水利，泄泻，痢疾，湿疹，荨麻疹，毒蛇咬伤。元胡：辛、苦、温。归肝、胃、心、肺、脾经。活血、散瘀、理气、止痛。用于心腹腰膝诸痛、月经不调、跌打损伤等。
桑椹子：甘、酸、寒。归肝、肾经。滋阴养血，生津，润肠。用于肝肾不足和血虚精亏的头晕目眩，腰酸耳鸣，须发早白，失眠多梦，津伤口渴，消渴，肠燥便秘等。
甘草：甘、平，归心、肺、脾、胃经。益气补中，清热解毒，祛痰止咳，缓急止痛，调和药性。用于心气不足的心动悸、脉结代，热毒疮疡，咽喉肿痛。
马齿苋：酸、性寒。归大肠、肝经。清热解毒，凉血止痢，除湿通淋。用于热毒泻痢，热淋，尿闭，赤白带下，崩漏，痔血，疮疡痈疖等。
本发明茯苓、玉米花健脾和胃、疏肝利胆，为君药，薄荷、八月札疏肝解郁、活血止痛，为臣药，万寿菊花、石椒草、黑节草、徐长卿、元胡、桑椹子、甘草、马齿苋行气活血、解毒止痛，滋阴养血，配伍使用，共奏健脾消积、疏肝止痛，行气活血之功，达到治疗非酒精性脂肪肝的目的。
本发明中药组合物使用于2007年至2010年临床观察非酒精性脂肪肝症100例患者，临床报告如下：
1、一般资料
100例患者中，女性52例，男性48例，年龄最小36岁，最大62岁，平均年龄45.6岁。
2、诊断标准
参照《中医病证诊断疗效标准》：
①无饮酒史或饮酒折合乙醇量，男性每周＜40g。②除外病毒性肝炎、药物性肝病、全胃肠性营养、肝豆状核变性等可导致脂肪肝的特定疾病。③除原发性疾病临床表现外，可伴乏力、消化不良、肝区隐痛、肝脾肿大等非特异性症状及体征。④可有体质量超重和(或)内脏性肥胖、空腹血糖增高、血脂紊乱、高血压等代谢综合征相关变化。⑤血清转氨酶和GGT水平可有轻至中轻度增高(＜5倍正常值上限)，通常以ALT增加为主。⑥肝脏影像学表现符合弥漫性脂肪肝影像学诊断要点。⑦肝活体组织检查组织学改变符合脂肪肝的病理学诊断要点。以上7项具备①～⑤项和第⑥或第⑦项中任一项可确定诊断。
3、治疗方法
3.1处方：茯苓30g，玉米花30g，薄荷25g，八月札25g，万寿菊花20g，石椒草20g，黑节草20g，徐长卿15g，元胡15g，桑椹子15g，甘草12g，马齿苋12g。
3.2制备方法：上述药物按常规工艺制成汤剂。
3.3服用方法：每次1剂，每日2次，30天为1疗程。
3.4观察指标：记录患者症状、体征变化及饮食、体质量情况。治疗前后行B超检查肝、胆、胰、脾，抽取静脉血检测血清血脂、肝功能水平，包括总胆固醇(TC)、三酰甘油(TG)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)。
4、治疗结果：
4.1参照《中医病证诊断疗效标准》：
临床治愈：临床症状及体征消失，肝脏B超或CT检查、实验室检查恢复正常；
显效：临床症状及体征明显改善，肝脏B超或CT检查，好转明显，实验室检查的各项指标下降40％以上；
未愈：临床症状及体征改善不明显，肝脏B超或CT检查治疗前后无明显变化，实验室检查的各项指标无明显下降。
4.2结果：100例患者中，临床治愈55例(55％)，显效38例(38％)，未愈7例(7％)，总有效率为93％。
5、典型病例
5.1孙某，男，50岁，肝功能示谷丙转氨酶(ALT)75U/L，谷草转氨酶(AST)45U/L，谷氨酰转肽酶(r-GGT)：58U/L，血脂：胆固醇5.59mmol/l，甘油三脂5.7mmol/L。CT显示：重度脂肪肝。服用本发明药物，治疗1个疗程，诸症减轻，继续服用3个疗程，复查肝功、血脂均正常，CT显示：肝胆脾胰未见明显异常，痊愈。半年后随访无复发。
5.2刘某，女，32岁，曾作肝功、血脂、彩超、CT等检查，确诊为非酒精性脂肪肝。血脂较高，转氨酶高。诊见舌红苔黄腻，脉滑数。服用本发明药物，每日1剂，1个疗程后，诸症减轻，继续服用1个疗程，复查肝功、血脂均正常，CT显示：肝胆脾胰未见明显异常，痊愈。半年后随访无复发。
具体实施方式
下面结合实施例对本发明作进一步的说明，下述该实施例仅用于说明本发明而对本发明没有限制。
实施例1，一种治疗非酒精性脂肪肝的中药组合物，它是由下述原料药制成：茯苓20g，玉米花20g，薄荷20g，八月札20g，万寿菊花15g，石椒草15g，黑节草15g，徐长卿10g，元胡10g，桑椹子8g，甘草8g，马齿苋8g。
实施例2，一种治疗非酒精性脂肪肝的中药组合物，它是由下述原料药制成：茯苓30g，玉米花30g，薄荷25g，八月札25g，万寿菊花20g，石椒草20g，黑节草20g，徐长卿15g，元胡15g，桑椹子12g，甘草12g，马齿苋12g。
实施例3，一种治疗非酒精性脂肪肝的中药组合物，它是由下述原料药制成：茯苓35g，玉米花35g，薄荷30g，八月札30g，万寿菊花25g，石椒草25g，黑节草25g，徐长卿18g，元胡18g，桑椹子15g，甘草15g，马齿苋15g。
Claims (2)
1.一种治疗非酒精性脂肪肝的中药组合物，其特征在于包括以下原料药：茯苓20-35份，玉米花20-35份，薄荷20-30份，八月札20-30份，万寿菊花15-25份，石椒草15-25份，黑节草15-25份，徐长卿10-18份，元胡10-18份，桑椹子8-15份，甘草8-15份，马齿苋8-15份。
2.根据权利要求1所述的中药组合物，其特征在包括以下原料药：
茯苓30份，玉米花30份，薄荷25份，八月札25份，万寿菊花20份，石椒草20份，黑节草20份，徐长卿15份，元胡15份，桑椹子12份，甘草12份，马齿苋12份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105263748A CN103007081B (zh) | 2012-11-27 | 2012-11-27 | 一种治疗非酒精性脂肪肝的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105263748A CN103007081B (zh) | 2012-11-27 | 2012-11-27 | 一种治疗非酒精性脂肪肝的中药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103007081A CN103007081A (zh) | 2013-04-03 |
| CN103007081B true CN103007081B (zh) | 2013-12-04 |
Family
ID=47956544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105263748A Expired - Fee Related CN103007081B (zh) | 2012-11-27 | 2012-11-27 | 一种治疗非酒精性脂肪肝的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103007081B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768289A (zh) * | 2014-01-27 | 2014-05-07 | 黄河科技学院 | 治疗非酒精性脂肪肝的马齿苋口服液及其制备方法 |
| CN103860884A (zh) * | 2014-04-01 | 2014-06-18 | 范东晨 | 一种治疗非酒精性脂肪肝的药剂 |
| CN105497509A (zh) * | 2014-11-07 | 2016-04-20 | 苏珉 | 一种治疗脂肪肝的中药 |
| CN106938014A (zh) * | 2017-02-17 | 2017-07-11 | 成都风靡生物科技有限公司 | 一种治疗非酒精性脂肪肝的汤剂药物及其制备方法 |
| CN113559144A (zh) * | 2021-08-27 | 2021-10-29 | 吉林大学 | 光果甘草粗提物在治疗非酒精性脂肪肝病中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007080A (zh) * | 2006-01-25 | 2007-08-01 | 张锡明 | 降脂利肝中药制剂 |
| CN101628098A (zh) * | 2008-07-18 | 2010-01-20 | 天科仁祥技术（北京）有限责任公司 | 一种治疗脂肪肝的药物组合及其制备方法 |
| CN101496894B (zh) * | 2009-03-19 | 2012-05-02 | 天津市传染病医院 | 治疗脂肪肝的药物及其制备方法 |
| DK2473045T3 (en) * | 2009-09-01 | 2016-12-12 | Catabasis Pharmaceuticals Inc | Niacin-FATTY ACID CONJUGATES AND THEIR USES |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| CN102058632B (zh) * | 2010-12-28 | 2012-05-30 | 吉林修正药业新药开发有限公司 | 一种药物组合物在制备防治酒精性肝损伤、脂肪肝及降血脂的药物中的应用 |
-
2012
- 2012-11-27 CN CN2012105263748A patent/CN103007081B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103007081A (zh) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103007081B (zh) | 一种治疗非酒精性脂肪肝的中药组合物 | |
| CN103083570A (zh) | 一种治疗过敏性紫癜的中药 | |
| CN101972424B (zh) | 治疗肝硬化腹水的中药 | |
| CN102178911B (zh) | 用于阳虚、痰湿体质人祛风除湿、通络止痛的中药制剂及其制备方法和应用 | |
| CN102552753B (zh) | 一种治疗子宫肌瘤的中药组合物 | |
| CN101618201B (zh) | 一种治疗外阴粘膜白斑的药物 | |
| CN103083573B (zh) | 一种治疗酒精性脂肪肝的中药 | |
| CN103721036B (zh) | 一种补肾益精的中药组合物 | |
| CN102755550B (zh) | 一种治疗乳糜尿的中药组合物 | |
| CN104107393A (zh) | 用于治疗风湿性关节炎的中药组合物 | |
| CN104013903A (zh) | 一种治疗婴儿湿疹的中药膏 | |
| CN103405679A (zh) | 一种治疗带状疱疹的中药组合物 | |
| CN103432528A (zh) | 一种治疗非酒精性脂肪肝的中药制剂 | |
| CN104208530A (zh) | 一种治疗小儿过敏性紫癜肾炎的中药制剂 | |
| CN103536790A (zh) | 一种治疗急性黄疸型肝炎的中药 | |
| CN104258206A (zh) | 一种治疗急性肾小球肾炎的中药制剂 | |
| CN105999038A (zh) | 一种治疗脾虚湿阻型病毒性肝炎的中药及其制备方法 | |
| CN103432473A (zh) | 有效治疗过敏性结肠炎的中药汤剂 | |
| CN105770293A (zh) | 治疗发烧的内服中药制剂 | |
| CN104491427A (zh) | 一种治疗脾虚肝郁型非酒精性脂肪肝的中药 | |
| CN105079373B (zh) | 一种用于治疗女性不孕不育的中药妇科垫 | |
| CN104800770A (zh) | 一种治疗儿童呼吸道感染的中药 | |
| CN104800435A (zh) | 一种治疗慢性盆腔炎的中药配方 | |
| CN103520584A (zh) | 一种治疗新生儿黄疸的中药及制备方法 | |
| CN103705770A (zh) | 一种治疗风疹的中药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: FANGCHENGGANG CITY PORT DISTRICT BALANCE ELECTRONI Free format text: FORMER OWNER: JU FAHONG Effective date: 20141212 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 262500 WEIFANG, SHANDONG PROVINCE TO: 538000 FANGCHENGGANG, GUANGXI ZHUANG AUTONOMOUS REGION |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141212 Address after: 538000 the Guangxi Zhuang Autonomous Region City, Fangchenggang port area before the intersection of the park and the intersection of the intersection of Dongxing Road, sea and sky are commercial and residential floor 11, No. 1108 Patentee after: FANGCHENGGANG CITY PORT DISTRICT BALANCE ELECTRONIC TECHNOLOGY CO., LTD. Address before: 262500 Shandong province Qingzhou City Linglong Mountain Road No. 3888 Qingzhou Invalides hospital Patentee before: Ju Fahong |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Shi Yefu Inventor before: Ju Fahong |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160613 Address after: 310023 B316 room, No. 16, No. 1, Ho Ho Road, Xihu District, Zhejiang, Hangzhou Patentee after: Hangzhou chiropractic Industrial Investment Co., Ltd. Address before: 538000 the Guangxi Zhuang Autonomous Region City, Fangchenggang port area before the intersection of the park and the intersection of the intersection of Dongxing Road, sea and sky are commercial and residential floor 11, No. 1108 Patentee before: FANGCHENGGANG CITY PORT DISTRICT BALANCE ELECTRONIC TECHNOLOGY CO., LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 Termination date: 20161127 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |